Advertisement

Current Anesthesiology Reports

, Volume 9, Issue 2, pp 85–91 | Cite as

Pharmacologic Treatment of Insomnia in Children and Adolescents with Chronic Pain Conditions

  • Víctor-Hugo González-Cárdenas
  • Evelyn Constantin
  • Marta Somaini
  • Anna Radzioch
  • Pablo M. IngelmoEmail author
Pediatric Anesthesia (J Lerman, Section Editor)
  • 35 Downloads
Part of the following topical collections:
  1. Pediatric Anesthesia

Abstract

Purpose of Review

The purpose of this chapter is to provide a review and expert opinion supporting pharmacological treatments for insomnia in children and adolescents with chronic pain conditions.

Recent Findings

Insomnia as an independent disorder is defined as dissatisfaction with sleep quantity or quality, clinically significant distress or impairment in daytime functioning, and a specific time pattern of occurrence. Independent of the pathological context, insomnia is more frequent in adolescents than in children. The impact of insomnia on pediatric patients is quite profound, especially on those affected by chronic pain, where the prevalence of insomnia is significantly greater than in those without pain. Despite the intense effect of insomnia on physical, emotional, and cognitive health, as well as on the efficacy of interdisciplinary therapy, currently, there are no pharmacological guidelines for this population. Thus, the diagnosis and successful treatment of insomnia in children with chronic pain conditions often represent a significant challenge for clinicians.

Summary

The management of insomnia requires an interdisciplinary team that includes a physician, physiotherapist, and psychologist. Specific therapies for insomnia include sleep hygiene counseling, cognitive behavioral therapy, and pharmacological interventions. This review focuses exclusively on five successful pharmacological treatments for insomnia in children and adolescents with chronic pain conditions, and presents concepts and recommendations based on current medical evidence and the knowledge of medical experts in the field.

Keywords

Sleep initiation and maintenance disorders Chronic pain Child Adolescent Drug therapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Víctor-Hugo González-Cárdenas, Evelyn Constantin, Marta Somaini, Anna Radzioch, and Pablo Ingelmo declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. In: Arlington, editor. 5th ed: American Psychiatric Publishing; 2013. Published in 2013, it is the current psychiatric mental disorder classification and include the diagnostic criteria for chronic insomnia. Google Scholar
  2. 2.
    •• Assembly of National Sleep Societies. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;27:675–700. Updated guideline for diagnosis and treatment of insomnia in Europe.Google Scholar
  3. 3.
    Winkelman JW. Clinical practice. Insomnia Disorder N Engl J Med. 2015;373(15):1437–44.Google Scholar
  4. 4.
    Owens JA, Rosen CL, Mindell JA. Medication use in the treatment of pediatric insomnia: results of a survey of community-based pediatricians. Pediatrics. 2003;111(5 Pt 1):e628–35.Google Scholar
  5. 5.
    Owens JA, Rosen CL, Mindell JA, Kirchner HL. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010;11(7):692–700.Google Scholar
  6. 6.
    • Hirshkowitz M, Whiton K, Albert SM, Alessi C, Bruni O, DonCarlos L, et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep Health. 2015;1(1):40–3. Sleep time duration definitions according to age range.Google Scholar
  7. 7.
    Owens JA, Mindell JA. Pediatric insomnia. Pediatr Clin N Am. 2011;8(3):555–69.Google Scholar
  8. 8.
    Hysing M, Pallesen S, Stormark KM, Lundervold AJ, Sivertsen B. Sleep patterns and insomnia among adolescents: a population-based study. J Sleep Res. 2013;22(5):549–56.Google Scholar
  9. 9.
    Fossum IN, Nordnes LT, Storemark SS, Bjorvatn B, Pallesen S. The association between use of electronic media in bed before going to sleep and insomnia symptoms, daytime sleepiness, morningness, and chronotype. Behav Sleep Med. 2014;12(5):343–57.Google Scholar
  10. 10.
    Merikanto I, Lahti T, Puusniekka R, Partonen T. Late bedtimes weaken school performance and predispose adolescents to health hazards. Sleep Med. 2013;14(11):1105–11.Google Scholar
  11. 11.
    Richardson C, Cain N, Bartel K, Micic G, Maddock B, Gradisar M. A randomised controlled trial of bright light therapy and morning activity for adolescents and young adults with delayed sleep-wake phase disorder. Sleep Med. 2018;45:114–23.Google Scholar
  12. 12.
    Richardson C, Cain N, Bartel K, Micic G, Maddock B, Gradisar M. Cognitive performance in adolescents with delayed sleep-wake phase disorder: treatment effects and a comparison with good sleepers. J Adolesc. 2018;65:72–84.Google Scholar
  13. 13.
    Zwart TC, Smits MG, Egberts TCG, Rademaker CMA, Van Geijlswijk IM. Long-term melatonin therapy for adolescents and young adults with chronic sleep onset insomnia and late melatonin onset: evaluation of sleep quality, chronotype, and lifestyle factors compared to age-related randomly selected population cohorts. Healthcare (Basel). 2018;6(1):E23.Google Scholar
  14. 14.
    Heath M, Johnston A, Dohnt H, Short M, Gradisar M. The role of pre-sleep cognitions in adolescent sleep-onset problems. Sleep Med. 2018;46:117–21.Google Scholar
  15. 15.
    Solheim B, Langsrud K, Kallestad H, Engstrøm M, Bjorvatn B, Sand T. Sleep structure and awakening threshold in delayed sleep-wake phase disorder patients compared to healthy sleepers. Sleep Med. 2018;46:61–8.Google Scholar
  16. 16.
    Pin Arboledas G, Merino Andreu M, de la Calle CT, Hidalgo Vicario MI, Rodriguez Hernandez PJ, Soto Insuga V, et al. Consensus document on the clinical use of melatonin in children and adolescents with sleep-onset insomnia. An Pediatr (Barc). 2014;81(5):328.e1–9.Google Scholar
  17. 17.
    Calhoun SL, Fernandez-Mendoza J, Vgontzas AN, Liao D, Bixler EO. Prevalence of insomnia symptoms in a general population sample of young children and preadolescents: gender effects. Sleep Med. 2014;15:91–5.Google Scholar
  18. 18.
    Nunes ML, Bruni O. Insomnia in childhood and adolescence: clinical aspects, diagnosis, and therapeutic approach. J Pediatr. 2015;91(6 Suppl 1):S26–35.Google Scholar
  19. 19.
    •• Karaman S, Karaman T, Dogru S, Onder Y, Citil R, Bulut YE, et al. Prevalence of sleep disturbance in chronic pain. Eur Rev Med Pharmacol Sci. 2014;18(17):2475–81. Analysis of the association between sleep disturbances (such as insomnia) and chronic pain.Google Scholar
  20. 20.
    Purushothaman B, Singh A, Lingutla K, Bhatia C, Pollock R, Krishna M. Prevalence of insomnia in patients with chronic back pain. J Orthop Surg (Hong Kong). 2013;21(1):68–70.Google Scholar
  21. 21.
    Park SJ, Lee R, Yoon DM, Yoon KB, Kim K, Kim SH. Factors associated with increased risk for pain catastrophizing in patients with chronic neck pain: a retrospective cross-sectional study. Medicine (Baltimore). 2016;95(37):e4698.Google Scholar
  22. 22.
    Palermo TM, Wilson AC, Lewandowski AS, Toliver-Sokol M, Murray CB. Behavioral and psychosocial factors associated with insomnia in adolescents with chronic pain. Pain. 2011;152(1):89–94.Google Scholar
  23. 23.
    Tang NKY, Sanborn AN. Better quality sleep promotes daytime physical activity in patients with chronic pain? A multilevel analysis of the within-person relationship. PLoS One. 2014;9(3):e92158.Google Scholar
  24. 24.
    •• Vega E, Beaulieu Y, Gauvin R, Ferland C, Stabile S, Pitt R, et al. Chronic non-cancer pain in children: we have a problem, but also solutions. Minerva Anestesiol. 2018;84(9):1081–92.Google Scholar
  25. 25.
    • Palermo TM, Law E, Churchill SS, Walker A. Longitudinal course and impact of insomnia symptoms in adolescents with and without chronic pain. J Pain. 2012;13(11):1099–106.Google Scholar
  26. 26.
    • Aasvik J, Stiles TC, Woodhouse A, Borchgrevink P, Inge Landrø N. The effect of insomnia on neuropsychological functioning in patients with comorbid symptoms of pain, fatigue, and mood disorders. Arch Clin Neuropsychol. 2018;33(1):14–23.Google Scholar
  27. 27.
    Kim SH, Lee DH, Yoon KB, An RJ, Yoon DM. Factors associated with increased risk for clinical insomnia in patients with chronic neck pain. Pain Physician. 2015;18(6):593–8.Google Scholar
  28. 28.
    Alföldi P, Wiklund T, Gerdle B. Comorbid insomnia in patients with chronic pain: a study based on the Swedish quality registry for pain rehabilitation (SQRP). Disabil Rehabil. 2014;36(20):1661–9.Google Scholar
  29. 29.
    Alföldi P, Dragioti H, Wiklund T, Gerdle B. Spreading of pain and insomnia in patients with chronic pain: results from a national quality registry (SQRP). J Rehabil Med. 2017;49(1):63–70.Google Scholar
  30. 30.
    van Geijlswijk IM, van der Heijden KB, Egberts AC, Korzilius HP, Smits MG. Dose findings of melatonin for chronic idiopatic childhood sleep onset insomnia. Ann RCT Psychopharmacology (Berl). 2010;212(3):379–91.Google Scholar
  31. 31.
    Eckerberg B, Lowden A, Nagai R, Akerstedt T. Melatonin treatment effects on adolescent students’ sleep timing and sleepiness in a placebo-controlled crossover study. Chronobiol Int. 2012;29(9):1239–48.Google Scholar
  32. 32.
    Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.Google Scholar
  33. 33.
    van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46(2):233–41.Google Scholar
  34. 34.
    van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010;33(12):1605–14.Google Scholar
  35. 35.
    Appleton RE, Jones AP, Gamble C, Williamson PR, Wiggs L, Montgomery P, et al. The use of melatonin in children with neurodevelopmental disorders and impaired sleep. Health Technol Assess. 2012;16:i-239.Google Scholar
  36. 36.
    Hoebert M, van der Heijden KB, van Geijlswijk IM, Smits MG. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res. 2009;47(1):1–7.Google Scholar
  37. 37.
    Emet M, Ozcan H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A. A review of melatonin, its receptors and drugs. Eurasian J Med. 2016;48(2):135–41.Google Scholar
  38. 38.
    Pelayo R, Yuen K. Pediatric sleep pharmacology. Child Adolesc Psychiatr Clin N Am. 2012;21(4):861–83.Google Scholar
  39. 39.
    Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry. 1996;35(5):599–605.Google Scholar
  40. 40.
    Barret J, Tracy D, Giaroli G. To sleep or not to sleep: a systematic review of the literature of pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescents Psychopharmacology. 2013;23(10):640–7.Google Scholar
  41. 41.
    Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders--a case series. Eur Child Adolesc Psychiatry. 2005;14(1):34–40.Google Scholar
  42. 42.
    Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 1993;32(2):350–3.Google Scholar
  43. 43.
    Wilens TE, Biederman J, Spencer T. Clonidine for sleep disturbance associated with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1994;33(3):424–6.Google Scholar
  44. 44.
    Nguyen M, Tharani S, Rahmani M, Shapiro M. A review of the use of clonidine as a sleep aid in the child and adolescent population. Clin Pediatr (Phila). 2014;53(3):211–6.Google Scholar
  45. 45.
    Mittur A. Trazodone: properties and utility in multiple disorders. Expert Rev Clin Pharmacol. 2011;4(2):181–96.Google Scholar
  46. 46.
    MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther. 2014;36(11):1676–701.Google Scholar
  47. 47.
    Lawlor BA, Newhouse PA, Balkin TJ, Molchan SE, Mellow AM, Murphy DL, et al. A preliminary study of the effects of night-time administration of the serotonin agonist, m-CPP, on sleep architecture and behaviour in healthy volunteers. Biol Psychiatry. 1991;29(3):281–6.Google Scholar
  48. 48.
    Emslie GJ, Kennard BD, Mayes TL, Nakonezny PA, Zhu L, Tao R, et al. Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth. J Child Adolesc Psychopharmacol. 2012;22(1):21–8.Google Scholar
  49. 49.
    Paterson LM, Nutt DJ, Ivarsson M, Hutson PH, Wilson SJ. Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers. J Psychopharmacol. 2009;23(5):487–94.Google Scholar
  50. 50.
    Zavesicka L, Brunovsky M, Horacek J, Matousek M, Sos P, Krajca V, et al. Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. Neuro Endocrinol Lett. 2008;29(6):895–901.Google Scholar
  51. 51.
    Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, et al. Antidepressants for insomnia in adults. Cochrane Database Syst Rev. 2018;5:CD010753.Google Scholar
  52. 52.
    Savarese M, Carnicelli M, Cardinali V, Mogavero MP, Federico F. Subjective hypnotic efficacy of trazodone and mirtazapine in patients with chronic insomnia: a retrospective, comparative study. Arch Ital Biol. 2015;153(2–3):231–8.Google Scholar
  53. 53.
    Fagiolini A, Amodeo G, Goracci A, Blardi P. Trazodone Contramid® in clinical practice: personalizing antidepressant intervention. Riv Psichiatr. 51(4):123–8.Google Scholar
  54. 54.
    Wichniak A, Wierzbicka A. The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine. Pol Merkur Lekarski. 2011;31(181):65–70.Google Scholar
  55. 55.
    Chen HC, Tsai SJ. Trazodone-induced severe headache. Psychiatry Clin Neurosci. 2011;65(7):681–2.Google Scholar
  56. 56.
    Wichniak A, Wierzbicka A, Jernajczyk W. Patients with insomnia and subthreshold depression show marked worsening of insomnia after discontinuation of sleep promoting medication. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(7):1671–6.Google Scholar
  57. 57.
    Monti JM, Spence DW, Buttoo K, Pandi-Perumal SR. Zolpidem’s use for insomnia. Asian J Psychiatr. 2017;25:79–90.Google Scholar
  58. 58.
    Shuaib W, Beatrice C, Abazid AG. Zolpidem overdose: a medical and ethical dilemma. Am J Ther. 2016;23(6):e1956-e7.Google Scholar
  59. 59.
    Blumer JL, Reed MD, Steinberg F, O’Riordan MA, Rosen CL, Springer MA, et al. Potential pharmacokinetic basis for zolpidem dosing in children with sleep difficulties. Clin Pharmacol Ther. 2008;83(4):551–8.Google Scholar
  60. 60.
    Yu ZH, Xu XH, Wang SD, Song MF, Liu Y, Yin Y, et al. Effect and safety of paroxetine combined with zolpidem in treatment of primary insomnia. Sleep Breath. 2017;21(1):191–5.Google Scholar
  61. 61.
    Beaulieu-Bonneau S, Ivers H, Guay B, Morin CM. Long-term maintenance of therapeutic gains associated with cognitive-behavioral therapy for insomnia delivered alone or combined with zolpidem. Sleep. 2017;1(40):zsx002.Google Scholar
  62. 62.
    Valente KD, Hasan R, Tavares SM, Gattaz WF. Lower doses of sublingual zolpidem are more effective than oral zolpidem to anticipate sleep onset in healthy volunteers. Sleep Med. 2013;14(1):20–3.Google Scholar
  63. 63.
    Health Canada. Sublinox (zolpidem tartrate), New Dosage Recommendations to Minimize Risk of Next-Day Impairment in Both Women and Men www.healthycanadians.gc.ca/recall-alert-rappelavis/hc-sc/2014/37415a-eng.php.
  64. 64.
    Food and Drug Administration. FDA Drug Safety Communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). www.fdagov/drugs/drugsafety/ucm334033htm. Accessed September 4, 2013.
  65. 65.
    Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age. Pediatrics. 2009;123(5):e770–6.Google Scholar
  66. 66.
    Licata SC, Mashhoon Y, Maclean RR, Lukas SE. Modest abuse related subjective effects of zolpidem in drug-naive volunteers. Behav Pharmacol. 2011;22(2):160–6.Google Scholar
  67. 67.
    Terán A, Majadas S, Galan J. Quetiapine in the treatment of sleep disturbances associated with addictive conditions: a retrospective study. Subst Use Misuse. 2008;43(14):2169–71.Google Scholar
  68. 68.
    Wiegand MH, Landry F, Brückner T, Pohl C, Veselý Z, Jahn T. Quetiapine in primary insomnia: a pilot study. Psychopharmacology. 2008;196(2):337–8.Google Scholar
  69. 69.
    Hermes EDA, Sernyak M, Rosenheck R. Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. Sleep. 2013;36(4):597–600.Google Scholar
  70. 70.
    Carney A. Efficacy of quetiapine off-label uses: data synthesis. J Psychosoc Nurs Ment Health Serv. 2013;51(8):11–8.Google Scholar
  71. 71.
    Fernando A, Chew G. Chronic insomnia secondary to chronic pain responding to quetiapine. Australas Psychiatry. 2005;13(1):86.Google Scholar
  72. 72.
    Cates ME, Jackson CW, Feldman JM, Stimmel AE, Woolley TW. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J. 2009;45(4):251–4.Google Scholar
  73. 73.
    Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother. 2012;46(5):718–22.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Víctor-Hugo González-Cárdenas
    • 1
    • 2
  • Evelyn Constantin
    • 3
    • 4
  • Marta Somaini
    • 1
  • Anna Radzioch
    • 1
  • Pablo M. Ingelmo
    • 1
    • 5
    • 6
    • 7
    • 8
    Email author
  1. 1.Chronic Pain Service, Montreal Children’s HospitalMcGill University Health CenterMontrealCanada
  2. 2.School of Medicine, University Children’s Hospital Foundation of San JoséUniversity Foundation for Health Sciences (FUCS)BogotáColombia
  3. 3.Child Health and Human Development Program, Department of PediatricsMontreal Children’s HospitalMontrealCanada
  4. 4.Department of Pediatrics, Faculty of MedicineMcGill UniversityMontrealCanada
  5. 5.The Alan Edwards Centre for Research on PainMcGill UniversityMontrealCanada
  6. 6.Department of Anesthesia, Faculty of MedicineMcGill UniversityMontrealCanada
  7. 7.CIMPARC (Consortium of Multidisciplinary Pain Researchers and Clinicians)MilanItaly
  8. 8.Department of AnesthesiaMontreal Children’s HospitalMontrealCanada

Personalised recommendations